Manni, Simona http://orcid.org/0000-0003-1845-6674
Del Bufalo, Francesca http://orcid.org/0000-0001-9643-3465
Merli, Pietro
Silvestris, Domenico Alessandro
Guercio, Marika
Caruso, Simona
Reddel, Sofia
Iaffaldano, Laura
Pezzella, Michele http://orcid.org/0000-0003-0088-7695
Di Cecca, Stefano
Sinibaldi, Matilde
Ottaviani, Alessio http://orcid.org/0000-0002-4796-3184
Quadraccia, Maria Cecilia http://orcid.org/0000-0002-4877-2793
Aurigemma, Mariasole http://orcid.org/0000-0003-2804-8770
Sarcinelli, Andrea http://orcid.org/0000-0002-8628-3878
Ciccone, Roselia
Abbaszadeh, Zeinab
Ceccarelli, Manuela http://orcid.org/0000-0001-8741-1600
De Vito, Rita
Lodi, Maria Chiara
Cefalo, Maria Giuseppina
Mastronuzzi, Angela http://orcid.org/0000-0002-4408-2373
De Angelis, Biagio http://orcid.org/0000-0002-7938-737X
Locatelli, Franco http://orcid.org/0000-0002-7976-3654
Quintarelli, Concetta
Funding for this research was provided by:
Ministero della Salute (RF-2021-12374120, GR-2016-02364546)
Associazione Italiana per la Ricerca sul Cancro (MFAG 21979, Special Project 5×1000 no. 9962 (F.L.))
Article History
Received: 23 March 2022
Accepted: 10 May 2023
First Online: 9 June 2023
Competing interests
: F.L. and P.M. declare the following competing interests: on September 2022 participated in an advisory board on primary HLH organized by Sobi, receiving honoraria. All the other authors do not have any competing interests to disclose. SOBI has not supported the study, besides the provision of the emapalumab drug.